. Author manuscript; available in PMC: 2023 Jul 1.

Published in final edited form as: Crit Care Med. 2022 Mar 14;50(7):1127–1137. doi: 10.1097/CCM.0000000000005535

Table 2.

Adjusted odds of PICU mortality, stratified based on pre-intubation exposure to respiratory support

Pre-Intubation Respiratory Support	No IC Diagnosis aOR [95% CI]^a	IC, not HCT aOR [95% CI]^a	HCT aOR [95% CI]^a
None	(reference)	(reference)	(reference)
HFNC	0.95 [0.70 – 1.29]	1.50 [1.11 – 2.03]	1.75 [1.07 – 2.86]
NIPPV	1.03 [0.78 – 1.36]	1.76 [1.31 – 2.35]	1.85 [1.12 – 3.02]

Mixed effects model, adjusted for patient-level fixed effects (IC diagnosis, age, gender, PIM-2 score) and center-level fixed effects (mean monthly volume of tracheal intubations). For each category of IC status, patients intubated without pre-intubation exposure to HFNC/NIPPV serve as the reference group.

IC: Immunocompromised; HCT: hematopoietic cell transplant; aOR: adjusted odds ratio; CI: confidence interval; HFNC: high-flow nasal cannula; NIPPV: noninvasive positive pressure ventilation.